blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3525796

EP3525796 - TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  11.10.2024
Database last updated on 30.10.2024
FormerGrant of patent is intended
Status updated on  14.02.2024
FormerExamination is in progress
Status updated on  29.04.2022
FormerRequest for examination was made
Status updated on  19.07.2019
FormerThe international publication has been made
Status updated on  20.04.2018
Formerunknown
Status updated on  08.11.2017
Most recent event   Tooltip11.10.2024Application deemed to be withdrawnpublished on 13.11.2024 [2024/46]
Applicant(s)For all designated states
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2019/34]
Inventor(s)01 / BENHADJI, Karim Adnane
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
02 / OAKLEY, Gerard Joseph, III
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis, Indiana 46206-6288 / US
 [2019/34]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2019/34]
Application number, filing date17791507.106.10.2017
[2019/34]
WO2017US55650
Priority number, dateUS201662407111P12.10.2016         Original published format: US 201662407111 P
[2019/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018071307
Date:19.04.2018
Language:EN
[2018/16]
Type: A1 Application with search report 
No.:EP3525796
Date:21.08.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 19.04.2018 takes the place of the publication of the European patent application.
[2019/34]
Search report(s)International search report - published on:EP19.04.2018
ClassificationIPC:A61K31/55, A61P35/00
[2019/34]
CPC:
A61K31/55 (EP,US); A61P35/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/34]
TitleGerman:GEZIELTE BEHANDLUNG VON REIFEM T-ZELLEN LYMPHOM[2024/11]
English:TARGETED TREATMENT OF MATURE T-CELL LYMPHOMA[2019/34]
French:TRAITEMENT DU LYMPHOME MATURE T-CELLULAIRE[2024/11]
Former [2019/34]GEZIELTE BEHANDLUNG VON REIFEM T-ZELL-LYMPHOM
Former [2019/34]TRAITEMENT CIBLÉ DE LYMPHOME À CELLULES T MATURES
Entry into regional phase13.05.2019National basic fee paid 
13.05.2019Designation fee(s) paid 
13.05.2019Examination fee paid 
Examination procedure13.05.2019Examination requested  [2019/34]
13.05.2019Date on which the examining division has become responsible
13.12.2019Amendment by applicant (claims and/or description)
03.05.2022Despatch of a communication from the examining division (Time limit: M04)
07.09.2022Reply to a communication from the examining division
28.02.2023Despatch of a communication from the examining division (Time limit: M04)
29.06.2023Reply to a communication from the examining division
15.02.2024Communication of intention to grant the patent
18.06.2024Application deemed to be withdrawn, date of legal effect  [2024/46]
09.07.2024Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2024/46]
Fees paidRenewal fee
21.10.2019Renewal fee patent year 03
14.10.2020Renewal fee patent year 04
29.09.2021Renewal fee patent year 05
15.09.2022Renewal fee patent year 06
13.09.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[AD]WO2013016081  (LILLY CO ELI [US], et al) [AD] 1-9* claim - *;
 [I]  - Anonymous, "NCT02784795 on 2016_05_26: A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", ClinicalTrials.gov Archive, (20160526), URL: https://clinicaltrials.gov/archive/NCT02784795/2016_05_26, (20170626), XP055384918 [I] 1-9 * the whole document *
 [I]  - Eunice Yuen, "Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in the first-in-man study", Cancer Research, (20160701), URL: http://cancerres.aacrjournals.org/content/76/14_Supplement/CT048, (20171020), XP055417836 [I] 1-9 * the whole document *

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2016-CT048
 [I]  - FIORELA N. HERNANDEZ TEJADA ET AL, "The Challenge of Targeting Notch in Hematologic Malignancies", FRONTIERS IN PEDIATRICS, (20140610), vol. 2, doi:10.3389/fped.2014.00054, XP055429841 [I] 1-9 * page 2 * * page 4 *

DOI:   http://dx.doi.org/10.3389/fped.2014.00054
 [A]  - Anonmous, "FS25 Peripheral T-Cell Lymphoma Facts I page 1 Revised", Leukemia & Lymphoma Society, (20140701), pages 1 - 8, URL: https://www.lls.org/sites/default/files/file_assets/peripheraltcelllymphomafacts.pdf, (20170830), XP055402418 [A] 1-9 * page 5 *
by applicantWO2013016081
    - S.M. BERGE et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, (19770100), vol. 66, no. 1, doi:doi:10.1002/jps.2600660104, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - Compendium of Organic Synthetic Methods, Wiley Interscience, (19740000), vol. 1-10
    - GRABHER et al., Nature Review Cancer, (20060000), vol. 6, pages 347 - 359
    - WENG et al., Science, (20040000), vol. 306, pages 269 - 271
    - PARK et al., Cancer Research, (20060000), vol. 66, pages 6312 - 6318
    - GAST et al., Genes. Chromosomes & Cancer, (20100000), vol. 49, pages 733 - 745
    - WESTHOFF et al., PNAS, (20090000), vol. 106, pages 22293 - 22298
    - RANGANATHAN et al., Nature Review Cancer, (20110000), vol. 11, pages 338 - 351
    - GUIJARRO et al., Am J Pathol, (20130000), vol. 182, no. 6, pages 2015 - 2027
    - SHIH et al., Cancer Research, (20070000), vol. 67, pages 1879 - 1882
    - CHESON et al., J. Clin. Oncol., (20070000), vol. 25, no. 5, pages 579 - 586
    - EISENHAUER et al., Eur J Cancer, (20090000), vol. 45, no. 2, pages 228 - 247
    - CHOI et al., J Clin Oncol., (20070000), vol. 25, no. 13, pages 1753 - 1759
    - OKEN et al., Am J Clin Oncol., (19820000), vol. 5, pages 649 - 655
    - YOUNG et al., Eur J Cancer, (19991203), vol. 5, no. 13, pages 1773 - 82
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.